Primary hypothyroidism Nutritional, Metabolic, Endocrine Other hypothyroidism
Conditions
Interventions
Each participant was allocated in random sequence to take thyroxine and placebo capsules, each for four months. During the thyroxine phase, participants started at a daily dose of 50 µg and this dose
Sponsors
Queen Mary University of London (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Women aged from 35 - 79 years, men aged from 65 - 79 years 2. Attended general screening at BUPA Wellness Centres between 1 January 2006 and 15 September 2007 3. Detected with thyroid stimulating hormone (TSH) greater than 4.0 mU/L
Exclusion criteria
Exclusion criteria: 1. People under current clinical surveillance for thyroid disease, or taking thyroxine, or having known pituitary or adrenal disease 2. People known to have coronary artery disease 3. People with any illness that in the doctor's opinion warranted exclusion from the trial 4. Diabetics taking insulin or oral hypoglycaemics, or people taking anticoagulants (warfarin or phenindinone) 5. People taking certain drugs that affect the serum concentration of TSH or free thyroxine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine how many participants feel better when taking thyroxine than placebo according to their own self-assessment, asked at the end of the 8 month trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the effects of thyroxine on: 1. General health 2. Symptom scores 3. Quality of life questionnaires 4. Cognitive function 5. Serum lipids Measured at the start of the study and at the end of the four month thyroxine and placebo phases. | — |
Countries
United Kingdom
Outcome results
None listed